Celgene ($CELG) is making a big purchase today. Its management wants Juno’s ($JUNO) pipeline of drugs and is willing to pay the premium. $CELG, Celgene Corporation / H1 Investors in CELG stock could get rattled with the $9 billion spending, although this is not as high as what it could have paid had biotech stocks not fallen in the last year. Juno before the buyout: $JUNO, JUNO THERAPEUTICS INC / H1 Instead of paying $10 - $11 billion, the $9 is fair value whereby Celgene will recapture the costs over time. Give Celgene 3 to 5 years before the deal is break-even on the balance sheet. After that, the unit will add positively to sales and profits.Related: $SGYP, $DVAX, $ACAD - Synergy, Dynavax, Acadia are buyout possiblities in the future.Gilead Sciences $GILD could still be in search of making more acquisitions.